EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Relevance of Creating a New Combined Anti-Tuberculosis Drug Based on a Fixed Combination of Isoniazid and Pyridoxine: Clinical, Marketing, Economic and Organizational Aspects

Alina Osyntseva

SSP Modern Pharmacy and Medicine · 29.04.2026 · 2 (6) · 49

DOI: 10.53933/aj5k5w51 ↗

Kurz gefasst

Fachartikel in der Zeitschrift SSP Modern Pharmacy and Medicine, online erschienen am 29.04.2026. Verfasst von Alina Osyntseva. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Modern pharmacotherapy of tuberculosis is characterized by the need for long-term use of multicomponent treatment regimens, which is accompanied by an increased risk of adverse reactions and a decrease in patients' adherence to therapy. One of the basic anti-tuberculosis drugs is Isoniazid, the use of which can cause neurotoxic complications that require prophylactic administration of Pyridoxine. At the same time, their combination in one dosage form is absent on the pharmaceutical market, which determines the relevance of creating a new combined drug. The purpose is to substantiate the relevance of creating a combined anti-tuberculosis drug based on a fixed combination of Isoniazid and Pyridoxine, considering clinical, marketing, economic and organizational aspects. Content analysis, structural-logical, marketing, comparative and price analysis are used. The sources of information were the data of the State Register of Medicines of Ukraine, the State Formulary of Medicines of Ukraine and information on the assortment, dosage forms, dosages, manufacturers, and price characteristics of drugs. It has been established that Isoniazid is widely represented both in the form of monopreparations and as part of combined drugs of etiotropic orientation, while Pyridoxine is presented mainly in the form of monopreparations. The absence of combined drugs combining Isoniazid and Pyridoxine was revealed, which indicates the presence of an unfilled niche in the pharmaceutical market. It has been shown that both active pharmaceutical ingredients are economically available, and their combination can be implemented within domestic production. The relevance of creating a new combined anti-tuberculosis drug based on Isoniazid and Pyridoxine, which is due to clinical (increasing safety and adherence to treatment), marketing (the presence of an unfilled market niche), economic (availability of components) and organizational (simplification of therapy regimens) aspects, has been substantiated.

Zitieren

APA

Osyntseva, A. (2026). The Relevance of Creating a New Combined Anti-Tuberculosis Drug Based on a Fixed Combination of Isoniazid and Pyridoxine: Clinical, Marketing, Economic and Organizational Aspects. SSP Modern Pharmacy and Medicine, 2(6), 49. https://doi.org/10.53933/aj5k5w51

Vancouver

Osyntseva A. The Relevance of Creating a New Combined Anti-Tuberculosis Drug Based on a Fixed Combination of Isoniazid and Pyridoxine: Clinical, Marketing, Economic and Organizational Aspects. SSP Modern Pharmacy and Medicine. 2026;2(6):49. doi:10.53933/aj5k5w51

BibTeX
@article{Osyntseva2026,
  author = {Osyntseva, Alina},
  title = {The Relevance of Creating a New Combined Anti-Tuberculosis Drug Based on a Fixed Combination of Isoniazid and Pyridoxine: Clinical, Marketing, Economic and Organizational Aspects},
  journal = {SSP Modern Pharmacy and Medicine},
  year = {2026},
  volume = {2},
  number = {6},
  pages = {49},
  doi = {10.53933/aj5k5w51}
}
Kostenlos starten →